Share Name Share Symbol Market Type Share ISIN Share Description
Clinigen Group Plc LSE:CLIN London Ordinary Share GB00B89J2419 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.05% 950.00 216,507 16:35:11
Bid Price Offer Price High Price Low Price Open Price
945.00 948.50 960.00 942.50 959.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 381.20 35.90 22.90 41.5 1,259
Last Trade Time Trade Type Trade Size Trade Price Currency
17:40:48 O 21 957.81 GBX

Clinigen (CLIN) Latest News

More Clinigen News
Clinigen Takeover Rumours

Clinigen (CLIN) Share Charts

1 Year Clinigen Chart

1 Year Clinigen Chart

1 Month Clinigen Chart

1 Month Clinigen Chart

Intraday Clinigen Chart

Intraday Clinigen Chart

Clinigen (CLIN) Discussions and Chat

Clinigen Forums and Chat

Date Time Title Posts
16/7/201907:08Clinigen - Speciality Pharmaceuticals922
04/7/201823:56Clinigen - solid looking growth stock93

Add a New Thread

Clinigen (CLIN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-07-19 16:41:44957.8121201.14O
2019-07-19 16:33:35950.005655,367.50O
2019-07-19 16:04:50949.961,0089,575.57O
2019-07-19 15:36:09950.006,00057,000.00O
2019-07-19 15:36:03950.006,00057,000.00O
View all Clinigen trades in real-time

Clinigen (CLIN) Top Chat Posts

Clinigen Daily Update: Clinigen Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CLIN. The last closing price for Clinigen was 949.50p.
Clinigen Group Plc has a 4 week average price of 935p and a 12 week average price of 935p.
The 1 year high share price is 1,069p while the 1 year low share price is currently 716p.
There are currently 132,479,167 shares in issue and the average daily traded volume is 314,393 shares. The market capitalisation of Clinigen Group Plc is £1,258,552,086.50.
garbut: Well they've raised the 80M @ share price of £8.45P and the CEO has bought 56K and a director over 32K. That means anyone buying in early enough in the morning will be getting them cheaper than the placees. Seems good to me.
pennypincher5: Hasn’t moved that much. Share price is still dismal - any insights? Seriously considering cutting my losses and dumping this one
maestrovitch666: This stock should be changed to Bill Murray because its like Groundhog and day watching the share price
healthtech: Overreaction. Commercial Medicines division is storming ahead and expected to grow further with Quantum Pharma pipeline. Clinical Trials Services gross profits dropped, which is what's driving this share price fall. At sub-900p, I'll buy more.
shaker44: Just watch out for continually heavy selling from Andrew Leaver and connections as they run down their founding stake.I got in and out as the share price takes 2 steps forward and 2-3 steps back. When the sell off is done it should be a good investment. All imo.
arc en ciel: Plus there's news of another drug to distribute. Looks like a good addition to the portfolio:
lomax99: Stock oversold. IC comment: Pharmaceutical group Clinigen (CLIN) gained support from investors when it first joined Aim in 2012, hailed for its position in a rapidly growing market and its highly experienced management team. Despite these factors remaining significant bull points, in the past few years the share price has failed to keep up the same momentum, and in recent months has seen a notable drop-off. This may in part be due to a slow first half caused by a large order for its key drug, Foscavir, slipping into the second six months, along with two big managed access contracts finishing. Also there appears to be some concern surrounding integration costs associated with two major acquisitions made in 2015. However, we feel these concerns have been overdone and see the recent share price weakness as an excellent opportunity to buy into the company's long-term growth. Idis and Link Healthcare, the two companies acquired in 2015, have improved Clinigen's business mix by reducing its reliance on erratic revenues from its clinical trials business - 18 per cent of first-half gross profit. Idis operates in two divisions, managed access and global access, which aim to provide physicians with treatments that are not available in their own country. These two divisions together contributed £19.1m of gross profits in the six months to December 2015, up from just £2.9m in the comparable period of the prior year. Link Healthcare was acquired in October and contributed £2.7m of revenue in just two months. Link provides commercial access to specialist medical technology products, specifically in Asia, Africa and Australasia, which expands both Clinigen's product range and its geographical reach. While integration costs associated with these acquisitions are likely to persist this year, Idis and Link are already boosting group earnings and brokers are forecasting significant upside in revenue and profits. The acquisitions were largely funded by extended banking facilities, which has stretched net debt to £82m. However, Clinigen is highly cash generative and net debt is forecast to fall to £23m by 2017, according to broker Numis. Specialist pharmaceuticals (SP) remains the largest contributor and accounted for almost a third of first-half gross profit. The group buys poorly managed drugs from big pharmaceutical companies and "revitalises" them, with the aim of doubling turnover by improving access to supply. The misconduct by Canadian company Valeant may have soured some investors' perception of such businesses, but Clinigen has a strong reputation. Foscavir, for the treatment of diseases associated with HIV, is the group's leading product. When it was acquired in 2010 it made £4.3m sales and in the most recent financial results it contributed £23m of revenue. While an order delay hit first-half performance, prospects remain good and Clinigen has developed a new 250ml bag, which it plans to replace the current glass bottle presentation of the drug. The bag is likely to widen Foscavir margins, enhance Clinigen's market share and, hopefully most notably, hold off generic competition. The company is trying to reduce its reliance on Foscavir by buying and developing new drugs, and added a sixth treatment, oncology support drug Totect, to its stable in March. In the first half, Clinigen's newer share price drugs increased sales by 74 per cent, taking their contribution to more than two-fifths of the division's total. Clinigen continues to demonstrate an impressive ability to revitalise drugs and is using acquisitions to branch out into new growth areas. Broker Numis believes the company can produce mid-double-digit annual earnings growth out to 2018, or more than 20 per cent a year, with the help of further acquisitions. That potential looks significantly undervalued by the shares' rating of just 15 times 2016 earnings. Buy.
3rd eye: Clinigen Group PLC 57.4% Potential Upside Indicated by Peel Hunt Posted by: Katherine Hargreaves 2nd March 2016 Clinigen Group PLC using EPIC/TICKER code LON:CLIN had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Peel Hunt. Clinigen Group PLC are listed in the Health Care sector within AIM. Peel Hunt have set their target price at 1000 GBX on its stock. This is indicating the analyst believes there is a potential upside of 57.4% from the opening price of 635.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 3.77805799999999 points and decreased 45 points respectively. Clinigen Group PLC LON:CLIN has a 50 day moving average of 652.97 GBX and a 200 day moving average of 670.64 GBX. The 1 year high for the share price is 773.5 GBX while the 52 week low for the share price is 495 GBX. There are currently 114,740,899 shares in issue with the average daily volume traded being 383,240. Market capitalisation for LON:CLIN is £731,358,378 GBP. Clinigen Group PLC is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
mechanical trader: Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe Date : 18/09/2014 @ 16:15 Source : RNS Non regulatory Stock : Clinigen (CLIN) Quote : 463.75 2.0 (0.43%) @ 16:20 HOME » LSE » LSE » Clinigen share price Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe Share On Facebook Print Alert TIDMCLIN Clinigen Group plc 18 September 2014 Clinigen Group launches New First-in-Class Antibiotic VIBATIV(R) (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe Burton-on-Trent, UK - 18 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV(R) (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia - HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. In March 2013, Clinigen, in-licensed V IBATIV(R) from Theravance, Inc. for commercialization in Europe, however, at that time the European Marketing Authorisation for the drug was suspended due to stopped operations at the previous manufacturer. Clinigen worked closely with a new contract manufacturer and the relevant European authorities to have the suspension lifted. The European Commission (EC) confirmed this in March 2014 enabling Europe-wide, licensed supply to commence. This will be the first time the licensed product will be available in Europe. VIBATIV(R) is an innovative treatment for HAP, the most common cause of death among infections acquired in a hospital setting, in that it offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus.([1]) The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that VIBATIV(R) may be less prone to resistance than other antibiotics. HAP caused by MRSA is a considerable unmet need, recognised as a public health priority in the EU. MRSA is estimated to cost EUR380 million every year in extra hospital costs.([2]) As a result of these high costs, both economic and human, there is increasing demand for new tools to combat infections caused by drug-resistant bacterial strains and the availability of new antibacterial agents is recognised as playing an important role in treating MRSA. 30-70% of patients who acquire HAP currently die despite early and appropriate treatment, and the condition places a large burden on healthcare systems.([3]) There is a limited choice of licensed antibiotic therapies able to treat HAP/VAP caused by MRSA and therefore this launch provides an important, alternative, effective agent in the fight against the growing problem of resistance by bacteria. "HAP caused by MRSA is often more serious and difficult to treat than similar infections with more drug susceptible strains," said Professor Matteo Bassetti, Professor of Infectious Diseases, School of Medicine and Postgraduate School of Infectious Diseases, University of Udine, Italy. "We are increasingly seeing bacteria acquire resistance to antibiotics previously considered last resort treatments; we need more options to treat these extremely serious infections. The widespread availability of a new and effective antibiotic such as VIBATIV(R) is therefore very good news for Europe." "The emergence of so-called 'super bugs' and increasing resistance among microbes to existing antibiotics has been recognised internationally as a major clinical challenge," said Peter George, Group Chief Executive Officer at Clinigen Group plc. "We are therefore extremely proud to be making this potentially life-saving medicine available across Europe for people who may have no other suitable option to fight a life-threatening infection." - Ends - About VIBATIV(R) (telavancin) VIBATIV(R) is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby VIBATIV(R) both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. VIBATIV(R) is approved in the United States (US) for the treatment of adult patients with (i) complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains, and (ii) hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. In September 2011, the European Commission granted Marketing Authorization for VIBATIV(R) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. VIBATIV(R) was discovered and developed by Theravance, Inc., and transferred to Theravance Biopharma, Inc. in connection with the separation of the two companies in June 2014. In May 2012, the European Commission suspended Marketing Authorization for VIBATIV(R) because the previous single-source drug product supplier did not meet the current Good Manufacturing Practice ("cGMP") requirements for the manufacture of VIBATIV(R). In March this year the European Commission reinstated the marketing authorisation for VIBATIV(R) as consistent product supply was re-established in accordance with European Commission requirements. Theravance Biopharma Antibiotics, Inc. has granted Clinigen exclusive commercialization rights to VIBATIV(R) in the EU and certain other European countries (including Switzerland and Norway). For further information, for healthcare professionals please visit About Clinigen The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen share price is focused on acquiring its own intellectual property in licensed, niche, hospital-only critical care medicines, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets. For more information, please visit Contact Details Clinigen Group plc Tel: +44 (0) 1283 495 010 Peter George, Group Chief Executive Officer Shaun Chilton, Chief Operating Officer
cestnous: The I. C. article; Buy ahead of Clinigen re-rating Bull points High margins Undervalued Experienced management Strong order book Bear points Lumpy revenue stream Disappointing 2013 After listing in late 2012, pharmaceutical group Clinigen (CLIN) fast become the darling of London’s junior Aim market. The listing price – 164p – surged to 690p early this year but some disappointments in half-year results in February led to a substantial share price fall. But with strong full-year numbers looking likely when the company reports its figures later this month, we think there is now considerable ground to make up on the upside. Investors therefore have a second opportunity to buy the stock, this time at a significant discount to 2013 levels. There are two main reasons Clinigen won rapturous support from investors when it arrived on the London Stock Exchange. The clinical trials market into which Clinigen supplies third-party material is growing at about 15 per cent a year. Secondly, Clinigen’s management had a proven track record in understanding the complex regulation surrounding specialist access to certain drugs – encompassed by its global access programme (GAP) division. But at the start of 2014, when Clinigen released half-year results for the six months to December, concerns started to build about the shares overheating. The clinical trial supply (CTS) division – responsible for more than 64 per cent of first-half sales – revealed a 13 per cent fall in sales to £39.5m, and it didn’t help that management admitted that a near four percentage point rise in the CTS gross profit margin – to 16.5 per cent – was ‘unsustainable’. Consequently, the shares crashed 17 per cent on the morning the news came out. But the company still holds substantial promise for future growth and increasing shareholder returns. The specialty pharmaceuticals division, which provides a solid backbone and accounted for just over half gross profits for the first six months of the year, is still in an early stage of development, with management aiming to add six new drugs over the next three to five years. Meanwhile, the CTS segment is forecast to grow 5 per cent in 2015, and GAP, which accounted for 16 per cent of first-half sales, continues to be Clinigen’s fastest-growing division. Encouragingly, chief executive Peter George says the lumpy nature of the CTS business and the drop in half-year sales was solely the result of strong comparative figures last year, which included a large number of low-margin anti-viral study sales. He also believes an overdependence on CTS revenues as the bulk of sales will soon be a thing of the past. A bullish trading update released at the end of July has already begun the re-rating of the stock. In it, Clinigen said it expects like-for-like sales growth of more than 7 per cent for 2014, with total revenues of no less than £126m. The GAP division is expected to report 50 per cent sales growth, and CTS should see revenues up more than 11 per cent in the second half compared with the first half. Continued improvement in gross margins across all the divisions also contributed to a 17 per cent improvement in underlying cash profits as at the end of June, suggesting full-year results should beat analysts’ expectations. Such a solid performance could be down to lower operational costs, and the keen prices paid for two newly acquired speciality pharma drugs: Cardioxane and Savene. And management says there is also potential in Clinigen’s new business pipeline for CTS and GAP, which broker N+1 Singer puts at about £200m. Come the 2014 annual results on 24 September, investors should glean further clarity on Clinigen’s new business pipeline and how the new speciality pharma products will help drive growth. This could provide the re-rating catalyst the stock needs. We think investors would do well to boost their stake in Clinigen while the shares trade on 16 times 2015 earnings. Buy. HR After losing its ‘hot stock’ status at the time of its half-year results in February, Clinigen looks set to re-rate
Clinigen share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190720 07:18:51